论文部分内容阅读
目的探讨注射用生长抑素联合多西他赛注射液和替吉奥胶囊治疗进展期胃癌的临床疗效。方法抽取中国人民解放军第八六医院2013年1月—2015年12月收治的胃癌患者86例,随机数字表格法将患者分为对照组和治疗组,每组各43例。对照组第1天静脉滴注多西他赛注射液75 mg/m2;口服替吉奥胶囊60 mg/m2,2次/d,于早饭后和晚饭后服用,连服21 d,之后停药14 d,作为1个周期,干预2个周期。治疗组在对照组基础上第1~5天微泵注射用生长抑素3 mg,持续6 h,2次/d,连续21 d,作为1个周期,干预2个周期。观察两组的临床疗效,比较两组治疗前后肿瘤标志物和血管内皮生长因子水平以及毒副反应情况。结果治疗后,对照组、治疗组的近期有效率分别为69.77%、88.37%,两组近期有效率比较差异有统计学意义(P<0.05)。治疗后,两组CA199、CEA、CA724水平均明显降低,同组治疗前后差异有统计学意义(P<0.05);治疗组CA199、CA724水平降低程度明显低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组血清VEGF-A、VEGF-C、VEGF-D水平均明显下降,同组治疗前后差异有统计学意义(P<0.05);治疗组这些观察指标的降低程度明显低于对照组,两组比较差异具有统计学意义(P<0.05)。两组患者血小板减少、中性粒细胞减少、恶心呕吐、肝损伤、腹泻不良反应发生率比较差异无统计学意义。结论注射用生长抑素联合多西他赛注射液和替吉奥胶囊治疗进展期胃癌具有较好的临床疗效,明显降低肿瘤标志物、血清血管内皮生长因子水平,减少不良反应,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of somatostatin and docetaxel injection for the treatment of advanced gastric cancer. Methods Totally 86 gastric cancer patients admitted to the 86th Hospital of Chinese People’s Liberation Army from January 2013 to December 2015 were divided into control group and treatment group by random number table method, 43 cases in each group. The control group received intravenous injection of docetaxel 75 mg / m 2 on day 1, and tioguan capsules 60 mg / m 2 and 2 times / d orally for breakfast and after dinner for 21 days, then discontinued 14 d, as one cycle, intervention 2 cycles. On the basis of the control group, the mice in the treatment group were injected with somatostatin 3 mg for 6 h twice a day for 21 consecutive days on the 1st to 5th day of the control group, and were treated as one cycle for 2 cycles. The clinical curative effect of the two groups was observed. The levels of tumor markers and vascular endothelial growth factor and toxicity before and after treatment were compared between the two groups. Results After treatment, the effective rates of the control group and the treatment group were 69.77% and 88.37%, respectively. There was significant difference in the short term effectiveness between the two groups (P <0.05). After treatment, the levels of CA199, CEA and CA724 in both groups were significantly decreased, the difference between the two groups was statistically significant (P <0.05); the levels of CA199 and CA724 in the treatment group were significantly lower than those in the control group Significance (P <0.05). After treatment, the serum levels of VEGF-A, VEGF-C and VEGF-D decreased significantly in both groups (P <0.05). The reduction of these indexes in the treatment group was significantly lower than that in the control group , The difference between the two groups was statistically significant (P <0.05). The incidence of thrombocytopenia, neutropenia, nausea and vomiting, liver injury and adverse reactions of diarrhea in the two groups had no significant difference. Conclusion Combined injection of somatostatin and docetaxel injection and tigeorgile capsule in the treatment of advanced gastric cancer have better clinical curative effect, significantly reduce the levels of tumor markers and serum vascular endothelial growth factor, reduce adverse reactions, and have certain clinical Promote the value of application.